Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.64 |
| ▸ | MTOR | P42345 | 15/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.54 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320502 | 1.00 | PIK3CA (0.64) | PIK3CAPIK3CDMTORCYP3A4RPTOR | |
| SCHEMBL14810438 | 0.92 | PIK3CA (0.64) | PIK3CAPIK3CDMTOR | |
| SCHEMBL16340848 | 0.92 | PIK3CA (0.56) | PIK3CAPIK3CDMTORRPTORMLST8 | |
| SCHEMBL16340846 | 0.92 | PIK3CA (0.56) | PIK3CAPIK3CDMTORRPTORMLST8 | |
| SCHEMBL14812167 | 0.92 | PIK3CA (0.64) | PIK3CAPIK3CDMTOR | |
| SCHEMBL16341266 | 0.92 | PIK3CA (0.54) | PIK3CAPIK3CDMTOR | |
| SCHEMBL14820970 | 0.92 | PIK3CA (0.54) | PIK3CAPIK3CDMTOR | |
| SCHEMBL14811324 | 0.91 | PIK3CA (0.58) | PIK3CAPIK3CDMTOR | |
| SCHEMBL14811326 | 0.91 | PIK3CA (0.58) | PIK3CAPIK3CDMTOR | |
| SCHEMBL2369976 | 0.91 | PIK3CD (0.59) | PIK3CAPIK3CDMTORCYP3A4RPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758379-B1 | Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases | CELLZOME LTD (GB) | 2016-10-19 | — | — | EP | claimed |
| US-9175011-B2 | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors | Cellzone Limited (GB) | 2015-11-03 | — | — | US | claimed |
| US-20140378438-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-12-25 | — | — | US | claimed |
| EP-2758379-B1 | Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases | CELLZOME LTD (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2758379-B1 | Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases | CELLZOME LTD (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9175011-B2 | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors | Cellzone Limited (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9175011-B2 | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors | Cellzone Limited (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9175011-B2 | Morpholino substituted urea or carbamate derivatives as MTOR inhibitors | Cellzone Limited (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20140378438-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378438-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378438-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| WO-2013041652-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378438-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, RPTOR | PIK3CA 400/4885PIK3CD 775/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.